cumberland pharmaceuticals search form search about usprofile  mission our strategy leadership team company history our products cumberland emerging technologies investor relationscorporate update corporate governancemanagement board of directors stock informationanalyst coverage historic stock lookup ownership profile financial informationsec fillings annual reports quarterly results key ratios events calender investor faqs news releasespress releases corporate updates in the news contact ir news contact us corporate headquarters cumberland pharmaceuticals inc  west end avenue suite  nashville tennessee  phone   toll free   fax   infocumberlandpharmacom for directions to us please see location employment opportunities employmentcumberlandpharmacom investor relations investorscumberlandpharmacom business development developmentcumberlandpharmacom wholesaler customer service phone   fax   medical information this website is not for medical emergencies if you are a patient caregiver or healthcare professional and need product related information please visit our products page which will link you to productspecific websites adverse event reporting toll free phone   for healthcare professionals only     providing solutions cumberland pharmaceuticals is a unique company with quality products that deliver real patient solutions every day quality products acetadote is an fdaapproved iv treatment for acetaminophen overdose currently being used in more than  us hospitals improving care caldolor is the first injectable treatment for pain and fever approved in the us driving success kristalose is the only prescription laxative product available in a powder formulation expanding pipeline hepatoren currently in phase ii is an injection intended to treat patients suffering from hepatorenal syndrome learn more about recent company developments from cumberland pharmaceuticals’ founder and ceo aj kazimiread message recent news july   clinigen and cumberland pharmaceuticals obtain fda approval for totect® in the us may   cumberland pharmaceuticals reports revenue growth of  in first quarter  view all cpix common stock exchange nasdaq open  price  change   volume  data as of monday   pm et minimum  minute delay cumberland pharmaceuticals inc  west end avenue suite  nashville tennessee   site mapprivacy policyterms  conditions our products  cumberland pharmaceuticals search form search about usprofile  mission our strategy leadership team company history our products cumberland emerging technologies investor relationscorporate update corporate governancemanagement board of directors stock informationanalyst coverage historic stock lookup ownership profile financial informationsec fillings annual reports quarterly results key ratios events calender investor faqs news releasespress releases corporate updates in the news contact ir news contact us corporate headquarters cumberland pharmaceuticals inc  west end avenue suite  nashville tennessee  phone   toll free   fax   infocumberlandpharmacom for directions to us please see location employment opportunities employmentcumberlandpharmacom investor relations investorscumberlandpharmacom business development developmentcumberlandpharmacom wholesaler customer service phone   fax   medical information this website is not for medical emergencies if you are a patient caregiver or healthcare professional and need product related information please visit our products page which will link you to productspecific websites adverse event reporting toll free phone   for healthcare professionals only     our products our product portfolio includes acetadote® acetylcysteine injection for the treatment of acetaminophen poisoning caldolor® ibuprofen injection the first injectable treatment for pain and fever approved in the united states and kristalose® lactulose for oral solution a prescription laxative vaprisol® conivaptan injection for the treatment of hyponatremia and omeclamox®pak for the treatment of h pylori and duodenal ulcer disease and ethyol® amifostine for injection for the treatment of oncology patients in early  we acquired the rights to ifetroban and are developing hepatoren® ifetroban injection for the treatment of hepatorenal syndrome boxaban® ifetroban oral capsule for the treatment of aspirinexacerbated respiratory disease vasculantm ifetroban oral capsule for the treatment of systemic sclerosis and portaban™ for the treatment of portal hypertension       phase preclinical preclinical phase  phase  phase  marketed acetadote® marketed acetadote® acetadote® is an fdaapproved iv treatment that prevents or reduces liver damage resulting from acetaminophen overdose the leading cause of drug toxicity in the us we developed and introduced the product in the united states in  and it is currently used in more than  us hospitals with a dose hour iv infusion acetadote® has the shortest fdaapproved treatment regimen for acetaminophen poisoning life saving treatment acetadote® is used in the emergency department the intensive care unit and hospital inpatient setting to prevent or lessen liver damage from an overdose of acetaminophen a common ingredient in many overthecounter and prescription medications though safe at recommended doses acetaminophen can cause liver damage with excessive use acetadote® is promoted by cumberland’s hospital sales force and has become a standard of care for the treatment of acetaminophen overdose in the us   visit httpwwwacetadotecom caldolor® marketed caldolor® caldolor® is indicated in adults and pediatric patients six months and older for the management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics as well as the reduction of fever it was the first fdaapproved intravenous therapy for fever improving patient care following completion of a development program involving more than  patients we received fda approval for caldolor® in june  we launched the product in september of that year and continued to introduce caldolor® to hospitals and surgical centers across the country through our organization during  caldolor® was stocked at a growing number of us medical facilities this was a result of a dedicated effort during the year to focus on individual hospital formulary approvals for the product as a result we were able to achieve approval and stocking of the product at a core group of medical facilities around the us we then initiated a shift in strategy to begin driving pullthrough use and corresponding sales of the product visit httpwwwcaldolorcom kristalose® marketed kristalose® kristalose® is the only branded prescription laxative product that features the established safety and efficacy of lactulose plus the convenience of a premeasured powder dose a unique dry powder crystalline formulation of lactulose kristalose® is designed to enhance patient compliance in the treatment of acute and chronic constipation it is the only prescription laxative available in premeasured powder packets making it easily portable kristalose® dissolves quickly in  oz of water offering patients a virtually tasteless gritfree and essentially caloriefree alternative to lactulose syrups there are no age limitations or length of use restrictions for kristalose® and it is the only osmotic prescription laxative still sampled to physicians in  we completed a patient preference study evaluating kristalose® compared to similar products in liquid forms the study which appeared in clinical and experimental gastroenterology demonstrated that  of patients in the study preferred the taste consistency and portability of kristalose® over similar products in liquid forms this data is highly relevant to our marketing activities for kristalose®   visit httpwwwkristalosecom hepatoren® phase  hepatoren® cumberland acquired the rights to ifetroban in early  ifetroban is a pharmacological antagonist of the thromboxane a  prostaglandin endoperoxide receptor tpr and has the potential to help multiple patient populations hepatoren® ifetroban injection is an injectable formulation of ifetroban being developed by cumberland to treat patients suffering from hepatorenal syndrome hrs cumberland is currently enrolling patients with hrs in a phase ii study of hepatoren® hrs is a lifethreatening condition involving reduced liver function and progressive kidney failure for which there is currently no fda approved pharmaceutical treatment approximately  patients in the united states suffer from medical conditions that make them susceptible to cirrhosis and a subset of these patients develop hrs every year      omeclamox®pak marketed omeclamox®pak omeclamox®pak  is a branded prescription product used for the treatment of helicobacter pylori h pylori infection and duodenal ulcer disease  it combines three wellknown and widely prescribed medications packaged together for patient convenience omeprazole clarithromycin and amoxicillin  it is the first fda approved triple therapy combination medication to contain omeprazole as the proton pump inhibitor which works to decrease the amount of acid the stomach produces  clarithromycin and amoxicillin are both antibiotic agents which hinder the growth of h pylori allowing the stomach lining to heal  with a simpletofollow day course of therapy omeclamoxpak has been shown to eradicate h pylori in up to  of patients the medications are packaged together on convenient daily dosing cards making it simple to follow the ampm twice a day dosing before meals  omeclamoxpak is available in over  retail pharmacies nationwide and is available on many managed care plan formularies   visit httpwwwomeclamoxcom vaprisol® marketed vaprisol® vaprisol® is the first and only intravenously administered vasopressin receptor antagonist a class of pharmaceuticals developed for the treatment of euvolemic and hypervolemic hyponatremia  vaprisol is indicated to raise serum sodium in hospitalized patients with euvolemic and hypervolemic hyponatremia  hyponatremia an imbalance of serum sodium to body water is the most common electrolyte disorder among hospitalized patients  vaprisol is premixed and administered by iv infusion the symptoms of hyponatremia range from fatigue mental confusion and abnormal gate to decreased consciousness and seizures  in severe cases coma and death may occur  hyponatremia may occur in a wide variety of hospitalized patients  treatment is often in a critical care setting  among the possible causes are stroke head trauma liver disease malignancy pulmonary failure renal failure druginduced and siadh syndrome of inappropriate antidiuretic hormone secretion   visit httpwwwvaprisolcom boxaban® phase  boxaban® in  cumberland announced the acquisition of the ifetroban program in collaboration with vanderbilt university and cumberland emerging technologies cet ifetroban is a pharmacological antagonist of the thromboxane a  prostaglandin endoperoxide receptor tpr and has the potential to help multiple patient populations boxaban® ifetroban oral capsule is being developed by cumberland to treat patients suffering from aspirinexacerbated respiratory disease aerd while also generating safety information that could allow ifetroban therapy to be considered for other patient populations cumberland received clearance for its investigational new drug ind application from the fda in early  to commence a phase ii study for boxaban® in patients with aerd aspirinexacerbated respiratory disease also known as samters triad is a respiratory disease involving chronic asthma and nasal polyposis that is worsened by aspirin or nonsteroidal antiinflammatory drugs current treatment of aerd remains a challenge as novel and effective treatment modalities are lacking for this unmet medical need approximately one in  asthmatic adults nearly  million patients in the united states suffer from aerd and the disease awareness is growing within the medical community     vasculan™ phase  vasculan™ in  we announced the acquisition of the ifetroban program in collaboration with vanderbilt university and cumberland emerging technologies cet ifetroban is a pharmacological antagonist of the thromboxane a  prostaglandin endoperoxide receptor tpr and has the potential to help multiple patient populations vasculan™ ifetroban oral capsule is being developed by cumberland for the treatment of systemic sclerosis ssc also called scleroderma it is a rare autoimmune disorder that affects the skin and internal organs with pulmonary disease emerging as the major cause of death in ssc patients preclinical work indicates that ifetroban is capable of preventing cardiac fibrosis in a model of pulmonary arterial hypertension ssc affects  million people worldwide and does not yet have a proven curative therapy although several medications are used to treat the skin disease associated with ssc there is no universally effective treatment to improve the function of affected internal organs such as the lungs heart and gastrointestinal tract hence the treatment of ssc remains an unmet need ethyol® marketed ethyol® ethyol® amifostine is an fdaapproved hospital product used in the prevention of xerostomia drymouth as a sideeffect of radiation treatment for head and neck cancer it is also indicated to reduce the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer we entered an exclusive agreement with clinigen group plc in  to commercialize ethyol® amifostine in the us under the terms of the agreement we are responsible for all marketing promotion and distribution of the product in the us this is our first oncology support product and is a good complement to our portfolio of specialty pharmaceuticals visit httpwwwethyolcom portaban™ phase  portaban™ cumberland acquired the rights to ifetroban in early  ifetroban is a pharmacological antagonist of the thromboxane a  prostaglandin endoperoxide receptor tpr and has the potential to help multiple patient populations portaban™ is an oral formulation of ifetroban and the fourth development candidate in cumberland’s pipeline preclinical studies have shown ifetroban can reduce portal pressure necrosis inflammation and fibrosis in multiple models of liver injury portal hypertension a complication of liver cirrhosis is an increase in the blood pressure within a system of veins called the portal venous system veins coming from the stomach intestine spleen and pancreas merge into the portal vein which then branches into smaller vessels and travels through the liver if the vessels in the liver are blocked due to liver damage blood cannot flow properly through the liver as a result high pressure in the portal system develops this increased pressure in the portal vein may lead to the development of large swollen veins varices within the esophagus stomach rectum or umbilical area belly button varices can rupture and bleed resulting in potentially lifethreatening complications cumberland pharmaceuticals inc  west end avenue suite  nashville tennessee  site mapprivacy policyterms  conditions leadership team  cumberland pharmaceuticals search form search about usprofile  mission our strategy leadership team company history our products cumberland emerging technologies investor relationscorporate update corporate governancemanagement board of directors stock informationanalyst coverage historic stock lookup ownership profile financial informationsec fillings annual reports quarterly results key ratios events calender investor faqs news releasespress releases corporate updates in the news contact ir news contact us corporate headquarters cumberland pharmaceuticals inc  west end avenue suite  nashville tennessee  phone   toll free   fax   infocumberlandpharmacom for directions to us please see location employment opportunities employmentcumberlandpharmacom investor relations investorscumberlandpharmacom business development developmentcumberlandpharmacom wholesaler customer service phone   fax   medical information this website is not for medical emergencies if you are a patient caregiver or healthcare professional and need product related information please visit our products page which will link you to productspecific websites adverse event reporting toll free phone   for healthcare professionals only     profile  mission our strategy leadership team company history aj kazimi chairman  chief executive officer gordon r bernard md director martin e cearnal director chief commercial officer  executive vice president jonathan i griggs director joey a jacobs director james r jones director caroline r young director kenneth j krogulski director aj kazimi chief executive officer martin e cearnal executive vice president  chief commercial officer leo pavliv rph executive vice president operations  chief development officer michael bonner senior director finance  accounting and chief financial officer james l herman senior vice president national accounts  chief compliance officer kelly a menzel senior director national hospital sales cindy patton senior director field sales  marketing barry lee director hospital products todd anthony senior director organizational development tan cheow choon senior director international business we are leading the way leadership team board of directors management team aj kazimi chairman  chief executive officer   mr kazimi has over twenty years experience in the international biopharmaceutical industry he has served as chief executive officer and chairman of the board of directors of cumberland pharmaceuticals a specialty pharmaceutical firm headquartered in nashville since the companys inception in  the company was twice named to the inc  list of fastest growing private firms in the us prior to its initial public offering and listing on the nasdaq stock exchange in  more recently cumberland was named one of the  fastest growing healthcare companies headquartered in the us by modern healthcare magazine in a listing that included hospital physician payersinsurers and supplier companies of all sizes prior to forming cumberland mr kazimi served as president and chief operating officer of therapeutic antibodies inc an international biopharmaceutical company during his eleven years with the company he oversaw operations in three countries and played a key role in the companys product development programs and licensing agreements during his tenure the company completed over  million in financings culminating in an ipo on the london stock exchange earlier in his career he worked at brownforman corporation a fortune  company rising through a series of management positions mr kazimi currently serves on the board of directors for the nashville health care council and nashville sports council he also serves as chairman of cet a biomedical incubator and joint initiative among cumberland vanderbilt university and the state of tennessees technology development corporation he has previously served on the boards of the tennessee biotechnology association and aegis sciences corporation a federally certified forensic toxicology laboratory he holds a bs from the university of notre dame and an mba from the vanderbilt owen graduate school of management member of the compensation committeechair of the nominating committee  gordon r bernard md director   dr bernard served as our medical director from  until  and currently serves as an advisor to the company as chair of our medical advisory board he has served on our board of directors since  dr bernard is the associate vicechancellor for research at vanderbilt university and also the melinda owen bass professor of medicine and former chief of the division of allergy pulmonary and critical care medicine at vanderbilt in addition he is senior associate dean for clinical sciences and chairman of vanderbilt’s pharmacy and therapeutics committee which is responsible for approving the vanderbilt medical center formulary of approved drugs and therapeutics dr bernard has been conducting national and international trials of pharmaceuticals since  and he has been steering committee chair of the national institutes of health acute respiratory distress syndrome clinical trials network since its inception in  this network is the only federally supported ongoing system for the conduct of research in the hospital intensive care unit or icu he holds a bs from the university of southwestern louisiana and an md from louisiana state university dr bernard maintains an active practice as an intensivist in the medical icu at vanderbilt and is therefore in a position to observe first hand the pharmaceutical management issues surrounding the care of a wide variety of the most severely ill patients and identify their unmet medical needs the board believes dr bernard’s medical background is extremely valuable as the company seeks to continue expanding its pipeline with promising products that offer advancement to patient care and are wellpositioned competitively martin e cearnal director chief commercial officer  executive vice president   mr cearnal has served as a member of our board of directors since  in  he joined our management team to head commercial development for cumberland currently serving as executive vice president and chief commercial officer he is the former president and chief executive officer of physicians world which became the largest provider of continuing medical education during his tenure from  to  physicians world was acquired by thomson healthcare in  and mr cearnal served as president of thomson physicians world from  to  and executive vice presidentchief strategy officer for thomson medical education from  through  he then became executive vice presidentchief strategy officer for jobson medical information mr cearnal has over  years of experience in the healthcare industry and has been involved with the launches of such noteworthy pharmaceutical products as lipitor® actos® introna® straterra® botox® and humira® he spent  years at revlon healthcare in a variety of domestic and international pharmaceutical marketing roles culminating in his position as vice president marketing for international operations he has a bs degree from southeast missouri state university the board believes mr cearnal brings significant marketingrelated knowledge to the company which has and will help facilitate successful product launches and marketing plans among other things jonathan i griggs director   mr griggs has served as a member of our board of directors since  his career spans more than  years in the pharmaceutical and biotechnology industries and includes significant international experience he spent  years at warner lambert corporation in positions of increasing responsibility culminating with his position as vice president of human resources during his tenure with warner lambert he provided leadership for the successful integration of three pharmaceutical businesses into what became parke davis the largest consolidation in the industry at that time from  to present he has been the ceo of griggs  associates a management and human resources consulting firm assisting startup companies and providing critical assistance in turnaround situations mr griggs also provided the leadership and strategic management for the formation and establishment of the aaca antique auto club of america museum a leading transportation museum where he served as chairman and is currently a director mr griggs has his bs degree from penn state and attended the wharton school of management at the university of pennsylvania he has been an advisor to cumberland pharmaceuticals as a member of the company’s pharmaceutical advisory board since it began operations in  the board believes mr griggs’ experience in strategic management and human resources consulting will be critical as the company continues to build a strong effective management team  member of the compensation committeechair of the nominating committee  joey a jacobs director   mr jacobs joined cumberland’s board of directors in  and is a member of the nominating committee a healthcare veteran with more than  years of industry experience mr jacobs is currently the chairman and chief executive officer of acadia healthcare a rapidly growing behavioral health company mr jacobs is the former chairman president and chief executive officer of nashvillebased psychiatric solutions inc psi which he cofounded in  and grew into a  billion behavioral healthcare system before the company’s sale to universal health services in  prior to founding psi mr jacobs spent  years at hospital corporation of america or hca where he served in various capacities including president of hca’s tennessee division mr jacobs’ background at hca also includes serving as president of hca’s central group vice president of the western group assistant vice president of the central group and assistant vice president of the salt lake city division in addition to serving as the former chairman of the nashville health care council he is also the past director of the federation of american hospitals and the national association of psychiatric health systems he is currently a board member of the monroe carell jr children’s hospital at vanderbilt and mental health management mr jacobs holds a bs degree from middle tennessee state university the board believes mr jacobs’ extensive hospital industry experience as well as his prior experience as chairman and ceo of a publicly traded healthcare company will be critical as the company continues to develop its hospital acute care product line and navigate the responsibilities associated with being a public company james r jones director   mr jones has served as a member of our board of directors since  mr jones’  year career in professional accounting at kpmg llp included the role of managing partner at their nashville tennessee office from  to  he served in various capacities during his career at kpmg which also included positions at their offices in jackson mississippi washington dc and greenville south carolina during his tenure with kpmg mr jones led a team of more than  individuals providing accounting services for an extensive client base following retirement in  he has served as an advisor and provided various consulting services to several companies including acting as liaison between management and the board of directors of a longterm care facility and serving as interim ceo of a charitable organization he is currently a board director and member of the audit committee of argent trust company of tennessee mr jones also serves as a member of our audit committee and is our audit committee financial expert mr jones holds a bs from mississippi college and an mba from mississippi state university the board believes mr jones’ significant accounting background will strengthen cumberland’s existing financial capabilities and play a key role as the company is subject to increasingly stringent accounting and auditing regulations as a public entity caroline r young director   ms young joined our board in  caroline is the prior president of the nashville health care council and founding executive director of the tennessee biotechnology association she was the president of the nashville health care council from  to  the council was formed as an association of the largest concentration of healthcare companies in the us which are headquartered in the nashville area it is one of the nation’s foremost health care industry associations and under caroline’s leadership membership grew to encompass  diverse organizations there she oversaw a series of international trade missions and launched oneofakind health care council fellows program designed to encompass the healthcare perspective and further develop the skills of senior business executives additionally she expanded the council’s innovative leadership health care program dedicated to nurturing the talents of the next generation of health care industry leaders prior to the council caroline was the founding executive director of tennessee biotechnology association now life science tennessee from  to  she also served in communications roles for the state of tennessee’s department of economic and community development from  to  currently caroline is the executive director of nashvillehealth an initiative focused on improving the health of citizens of the metropolitan nashville area of tennessee nashvillehealth was founded by former us senate majority leader bill frist with the support from the robert wood johnson foundation caroline has been recognized by the nashville business journal as a “healthcare hero” and the nashville medical news as a “woman to watch” kenneth j krogulski director   mr krogulski joined cumberland’s board of directors in  he has over  years of experience in security analysis and portfolio management and is currently the president and chief executive officer of berkshire asset management llc as well as the company’s chief investment officer berkshire is a yearold independent sec registered pennsylvania based investment advisory firm with over  billion in assets under supervision prior to berkshire mr krogulski began his career in financial services in  at first eastern bank na now pnc financial as an investment analyst and portfolio manager where he advanced to chief investment officer of the trust department he then joined berkshire in  and later led a management buyout acquiring the company from legg mason under his leadership berkshire’s assets under supervision have grown from  million in  and are now over  billion currently mr krogulski serves on the board of allied services rehabilitation hospital and as chairman of the appleseed foundation previously he served as the director of the wyoming valley health care system on the board of the fm kirby center for the performing arts the luzerne foundation and on various other community boards mr krogulski earned his mba from wilkes university and a bs in finance from indiana university of pennsylvania in addition he holds the chartered financial analyst designation aj kazimi chief executive officer   mr kazimi founded cumberland pharmaceuticals in  and has served as chief executive officer and chairman of the board of directors since its inception prior to forming cumberland he served as president and chief operating officer of therapeutic antibodies inc a biopharmaceutical company during his  years with the company mr kazimi oversaw operations in three countries and played a key role in the company’s product development strategies licensing and distribution agreements and the raising of more than  million through equity and debt financings as well as its initial public offering earlier in his career he worked at brownforman corporation rising through a series of management positions mr kazimi currently serves on the board of directors for the nashville health care council an industry association representing the largest concentration of healthcare companies in the united states and has served on the board for aegis toxicology sciences corporation a federally certified forensic toxicology laboratory he also serves as chairman and chief executive officer of cumberland emerging technologies inc cet he holds a bs from the university of notre dame and an mba from the vanderbilt owen graduate school of management martin e cearnal executive vice president  chief commercial officer   prior to joining cumberland as senior vice president of commercial development in  mr cearnal served as president and chief executive officer of physicians world during his year tenure the company became the largest provider of continuing medical education before its acquisition by thomson healthcare in  he served as president of thomson physicians world from  to  and executive vice presidentchief strategy officer for thomson medical education from  through  during his more than  years in the healthcare industry mr cearnal has been involved with the launches of such noteworthy pharmaceutical products as lipitor® actos® introna® straterra® botox® and humira® he spent  years at revlon healthcare in a variety of domestic and international pharmaceutical marketing roles culminating in his position as vice president marketing for international operations mr cearnal has also served on cumberland’s board of directors since  he is a graduate of southeast missouri state university leo pavliv rph executive vice president operations  chief development officer   as executive vice president of operations mr pavliv is responsible for cumberland’s overall drug development including manufacturing and quality operations prior to joining cumberland in  he spent six years at cato research a contract research organization where he served in a variety of positions including vice president of pharmaceutical development previously he held scientific and management positions at both large pharmaceutical and smaller biopharmaceutical firms including parkedavis agouron pharmaceuticals procyte and interferon sciences he is a registered pharmacist rph and is regulatory affairs certified rac mr pavliv holds a bs pharmacy and an mba from rutgers university michael bonner senior director finance  accounting and chief financial officer   mr bonner has more than  years of experience in financial management accounting and reporting primarily within the health care industry prior to joining cumberland mr bonner worked for over six years with advocat inc a  million nasdaq listed skilled nursing services provider as vice president of accounting and financial reporting prior to that mr bonner served in a financial reporting role at lifepoint hospitals inc a nasdaq listed acute care hospital company he started his career at ernst  young where he spent close to five years in their assurance practice a certified public accountant mr bonner holds both a bachelor of science in accounting and a masters of business administration james l herman senior vice president national accounts  chief compliance officer   as senior vice president of national accounts mr herman handles all national sales including wholesalers and retail chain buying offices managed care home offices and federal government accounts he also oversees corporate compliance efforts previously he was with solvay pharmaceuticals where he served as director of managed care as well as director of trade affairs and customer service earlier in his career mr herman spent eight years with schwarz pharma where he held national sales leadership positions he holds a bs from indiana university and an mba from cardinal stritch university kelly a menzel senior director national hospital sales   ms menzel joined our company to launch acetadote as a regional hospital sales representative in the midatlantic in  in addition to launching acetadote she acted as the field based trainer and was then promoted to the eastern district regional manager position in  ms menzel was named as director of hospital sales in  at the launch of caldolor she is responsible for all sales activities associated with our hospital products prior to working for cumberland ms menzel was a hospital sales representative for roche laboratories selling injectable antibiotics and other injectable products to the hospital market previous to her entry into pharmaceuticals ms menzel held various management positions in the sales hospitality and banking industries spanning  years she has a bachelor of science degree from towson university in towson maryland cindy patton senior director field sales  marketing   ms patton began her industry career as a ciba geigy sales representative in  relocating to the ciba geigy corporate office in  she served in the customer marketing group becoming the director of institutional marketing in  following the merger that created novartis she held positions which included lotensin product director and ciba novartis sales director for the new york region she graduated magna cum laude from lambuth college with a bba barry lee director hospital products   in his role as director hospital products mr lee is responsible for all marketing activities associated with the commercialization of caldolor® the company’s intravenous formulation of ibuprofen prior to joining the company in  he spent  years with bayer healthcare pharmaceuticals inc there he held a variety of pharmaceutical sales and marketing positions and most notably was responsible for the launch of yasmin® in —one of the most successful industry product launches at that time he earned a bs degree from texas am university todd anthony senior director organizational development   mr anthony joined our company in  as director sales training  development he is responsible for all training activities related to product knowledge and selling skills for our sales organization as well as sales management corporate training and leadership development he began his pharmaceutical career with berlex laboratories inc in  and spent  years at that company which is now bayer healthcare pharmaceuticals following the  acquisition of schering ag while there he held positions of increasing responsibility including roles in sales sales training sales management and corporate managementleadership development he has a bsn degree from d’youville college in buffalo ny tan cheow choon senior director international business   as senior director of international business tan cheow choon joined our company in  he is responsible for executing cumberland’s initiative to expand markets for its products across asia including establishing building and managing the company’s presence there prior to joining the company choon was in a variety of senior management roles at international pharmaceutical firms most recently as vice president of southeast asia for hospira inc choon joined hospira pursuant to the company’s  acquisition of mayne pharma sea pte ltd formerly known as faulding pharmaceuticals or “faulding” and was instrumental in the successful integration of the two pharmaceutical companies activities in their asian markets during his year tenure with faulding also a global provider of injectable hospital products choon served in a variety of senior management business development and marketing capacities playing a key role in growing faulding’s presence in asia he has a bachelor of accountancy from the national university of singapore and a mba from monash university in australia cumberland pharmaceuticals inc  west end avenue suite  nashville tennessee  site mapprivacy policyterms  conditions history  cumberland pharmaceuticals search form search about usprofile  mission our strategy leadership team company history our products cumberland emerging technologies investor relationscorporate update corporate governancemanagement board of directors stock informationanalyst coverage historic stock lookup ownership profile financial informationsec fillings annual reports quarterly results key ratios events calender investor faqs news releasespress releases corporate updates in the news contact ir news contact us corporate headquarters cumberland pharmaceuticals inc  west end avenue suite  nashville tennessee  phone   toll free   fax   infocumberlandpharmacom for directions to us please see location employment opportunities employmentcumberlandpharmacom investor relations investorscumberlandpharmacom business development developmentcumberlandpharmacom wholesaler customer service phone   fax   medical information this website is not for medical emergencies if you are a patient caregiver or healthcare professional and need product related information please visit our products page which will link you to productspecific websites adverse event reporting toll free phone   for healthcare professionals only     profile  mission our strategy leadership team company history business milestones company history cumberland pharmaceuticals and its leadership have been honored with a variety of awards recognizing the company’s entrepreneurial spirit and business success  in may  cumberland and clinigen group announce the entrance into a us commercialization agreement for the oncology support drug ethyol®  cumberland announces new development program to develop vasculantm oral capsule for the treatment of systemic sclerosis cumberland and piramal critical care announce the launch of a caldolor® and vaprisol® copromotion throughout the us  cumberland announces the approval of caldolor® ibuprofen injection for pediatric patients six months of age and older in september  cumberland and clinigen group announce a strategic alliance to maximize the potential of future commercial products cumberland expands pipeline with boxaban® ifetroban oral capsule for the treatment of asprinexacerbated respiratory disease  cumberland announces fifth commercial product vaprisol® for the treatment of hyponatremia in may  cumberland and gloria pharmaceuticals announce  million investment in joint research  development initiatives with cet  cumberland announces fourth commercial product omeclamox® pax for the treatment of hpylori  cumberland is named to modern healthcare’s inaugural healthcare’s hottest list honoring healthcare’s  fastest growing healthcare companies cumberland pharmaceuticals is named as a finalist in the nashville business journal’s “best in business” competition  cumberland pharmaceuticals named to as one of the fastest growing companies in north america on deloittes  technology fast ™ list for the second consecutive year in november  cumberland reached an agreement to acquire the fda registration and trademark for kristalose® from mylan pharmaceuticals cumberland pharmaceuticals launches next generation acetadote® product  cumberland ceo aj kazimi is named a finalist for ernst  young’s entrepreneur of the year® award in alabamageorgiatennessee for the second consecutive year cumberland pharmaceuticals is once again recognized as a finalist in the nashville business journal’s best in business competition  cumberland launches caldolor® the first injectable treatment for pain and fever approved in the us cumberland completes initial public offering  and share listing on nasdaq exchange  the nashville business journal honors cumberland ceo aj kazimi as a healthcare hero – company leader  cumberland ceo aj kazimi is presented vanderbilt university’s owen graduate school of management distinguished alumni award cumberland is named to the inc  list of america’s fastest growing private companies cumberland launches kristalose® the only prescription laxative product available in a powder formulation for the treatment of acute and chronic constipation  cumberland is named to business tennessee magazine’s fast  list for a second year in a row cumberland is honored with a music city future  award which recognizes the region’s most successful private companies  cumberland is recognized as one business tennessee magazine’s fast  private companies cumberland pharmaceuticals launches their first fda approved product acetadote® for the treatment for acetaminophen overdose   cumberland pharmaceuticals inc  west end avenue suite  nashville tennessee  site mapprivacy policyterms  conditions terms  conditions  cumberland pharmaceuticals search form search about usprofile  mission our strategy leadership team company history our products cumberland emerging technologies investor relationscorporate update corporate governancemanagement board of directors stock informationanalyst coverage historic stock lookup ownership profile financial informationsec fillings annual reports quarterly results key ratios events calender investor faqs news releasespress releases corporate updates in the news contact ir news contact us corporate headquarters cumberland pharmaceuticals inc  west end avenue suite  nashville tennessee  phone   toll free   fax   infocumberlandpharmacom for directions to us please see location employment opportunities employmentcumberlandpharmacom investor relations investorscumberlandpharmacom business development developmentcumberlandpharmacom wholesaler customer service phone   fax   medical information this website is not for medical emergencies if you are a patient caregiver or healthcare professional and need product related information please visit our products page which will link you to productspecific websites adverse event reporting toll free phone   for healthcare professionals only     terms of use   last updated  june     cumberland pharmaceuticals inc “cumberland” provides the opportunity for users of wwwcumberlandpharmacom and related websites where this policy appears the “site” to access and review information about our products and to learn about cumberland the “services”  please read the following terms and conditions “terms of use” carefully  these terms of use govern your access to and use of the site services and cumberland content defined below under the heading “restrictions on use”  these terms of use constitute a binding legal agreement between you and cumberland and apply to your relationship with cumberland   you acknowledge and agree that by visiting accessing or using the site or services or by downloading any cumberland content from the site or through the services you are indicating that you have read understand and agree to be bound by these terms of use  if you agree to these terms of use on behalf of an entity you represent and warrant that you have the authority to bind that entity to these terms of use and your agreement to these terms of use will be treated as the agreement of such entity  in that event “you” and “your” refer herein to that entity   if you do not agree to these terms then you have no right to access or use the site services or cumberland content   by using this site you acknowledge that cumberland is providing the material for informational purposes only and that neither cumberland nor its agents affiliates partners or licensors are providing the materials to you for the purposes of giving you advice for medical or other purposes  you should not rely on the materials in deciding on a treatment plan drug usage or any other medical advice regarding the materials or any investment decisions and cumberland and its licensors strongly urge that you consult with a physician or financial advisor in connection with any and all options that may be available to you      eligibility the site and services are intended solely for persons who are  or older  any access to or use of the site or services by anyone under  is expressly prohibited  by accessing or using the site or services you represent and warrant that you are  or older      ownership the site services and cumberland content are protected by copyright trademark and other laws of the united states and foreign countries  cumberland and its licensors exclusively own all right title and interest in and to the site services and cumberland content including all associated intellectual property rights  you will not remove alter or obscure any copyright trademark service mark or other proprietary rights notices incorporated in or accompanying the site services or cumberland content  no licenses or rights are granted to you by implication or otherwise in or to any intellectual property rights owned or controlled by cumberland or its licensors     restrictions on use “cumberland content” means all text images graphics photos video or audiovisual files white papers datasheets documents informational materials or any other content provided via the site and services by cumberland  subject to your compliance with the terms and conditions of these terms of use cumberland authorizes you to download view and print any cumberland content solely for your personal and noncommercial use and subject to the terms and restrictions set forth in these terms of use      general prohibitions you agree not to do any of the following while using the site services or cumberland content   use display mirror frame or utilize framing techniques to enclose the site or any individual element or materials within the site cumberland’s name any cumberland trademark logo or other proprietary information the content of any text or the layout and design of any page or form contained on a page without cumberland’s express written consent copy modify adapt improve enhance or make any derivative work from the site services or cumberland content in whole or in part distribute license sell transfer publicly display publicly perform transmit stream broadcast or otherwise exploit the site services or cumberland content in whole or in part access tamper with or use nonpublic areas of the site cumberland’s computer systems or the technical delivery systems of cumberland’s providers attempt to probe scan or test the vulnerability of any cumberland system or network or breach any security or authentication measures avoid bypass remove deactivate impair descramble or otherwise circumvent any technological measure implemented by cumberland or any of cumberland’s providers to protect the site services or cumberland content attempt to access or search the site services or cumberland content or download cumberland content from the site or services through the use of any engine software tool agent device or mechanism including spiders robots crawlers data mining tools or the like other than the software andor search agents provided by cumberland or other generally available third party web browsers such as microsoft internet explorer mozilla firefox safari or opera use any meta tags or other hidden text code or metadata utilizing a cumberland trademark logo url or product name without cumberland’s express written consent use the site services or cumberland content for any commercial purpose or the benefit of any third party or in any manner not permitted by these terms of use forge any tcpip packet header or any part of the header information in any email or in any way use the site services or cumberland content to send altered deceptive or false sourceidentifying information attempt to decipher decompile disassemble or reverse engineer any of the software used to provide the site services or cumberland content interfere with or attempt to interfere with the access of any user host hardware system or network connected to the site including without limitation sending a virus overloading flooding spamming or mailbombing the site violate any applicable law or regulation or encourage or enable any other individual to do any of the foregoing   cumberland will have the right to investigate and prosecute violations of any of the above including intellectual property rights infringement and site security issues to the fullest extent of the law  cumberland may involve and cooperate with law enforcement authorities in prosecuting users who violate these terms of use or applicable law  you acknowledge that cumberland has no obligation to monitor your access to or use of the site services or cumberland content but has the right to do so for the purpose of operating the site and services to ensure your compliance with these terms of use or to comply with applicable law or the order or requirement of a court administrative agency or other governmental body  cumberland reserves the right at any time and without prior notice to remove or disable access to any cumberland content     trademarks cumberland pharmaceuticals® is a registered trademark of cumberland pharmaceuticals inc  other trademarks service marks logos and trade names appearing on this site are the property of cumberland or their respective owners  cumberland and any party that provided trademarks service marks logos and trade names to cumberland retain all rights with respect thereto  nothing on this site shall be construed as granting by implication estoppel or otherwise any license or right to use any trademark service mark logo or trade name displayed on the site  unauthorized use of any trademarks service marks or logos used on the site may be a violation of state national and international trademark laws  additionally cumberland’s custom icons graphics logos and scripting on the site are covered by trademark trade dress copyright or other property right law and may not be copied modified or used in whole or in part     links the site may contain links to thirdparty websites or resources  you acknowledge and agree that cumberland is not responsible or liable for i the availability or accuracy of such websites or resources or ii the content products or services on or available from such websites or resources  links to such websites or resources do not imply any endorsement by cumberland of such websites or resources or the content products or services available from such websites or resources  you acknowledge sole responsibility for and assume all risk arising from your use of any such websites or resources  cumberland makes no representations or warranties about the content completeness or accuracy of the links or the sites linked to this site     disclaimers the site services and cumberland content are provided “as is” without warranty of any kind including but not limited to express or implied with regard to the information content materials or products included on this site  without limiting the foregoing cumberland explicitly disclaims any warranties of merchantability fitness for a particular purpose quiet enjoyment or noninfringement of intellectual property rights or other proprietary rights freedom from computer virus and any warranties arising out of course of dealing or usage of trade   cumberland makes no warranty that the site services or cumberland content will meet your requirements or be available on an uninterrupted secure or errorfree basis  cumberland makes no warranty regarding the quality of any services or cumberland content obtained through the site or services or the accuracy timeliness completeness or reliability of any cumberland content or information obtained through the site or services   cumberland does not guarantee or warrant that the files available for downloading from the site will be free of viruses worms trojan horses or other code that may manifest contaminating or destructive properties  cumberland does not assume any responsibility or risk for your use of this site   no advice or information whether oral or written obtained from cumberland or through the site services or cumberland content will create any warranty not expressly made herein   the financial information on the site is provided as a convenience for stockholders and is for informational purposes only this information is not intended and should not be relied upon for trading purposes or any investment decisions neither cumberland nor its agents affiliates partners licensors or data providers guarantee the accuracy or completeness of any stock price or other information displayed nor shall any such party be liable in any way to the user of the information or to any other person for any delays inaccuracies errors in or omission of any such information or the transmission thereof or for any actions taken in reliance thereon or for any damages arising therefrom or occasioned thereby investors are reminded that historical and current stock price performance data are not necessarily indicative of future performance cumberland its agents affiliates partners licensors and data providers strongly urge that you consult with a financial advisor in connection with any and all options that may be available to you        cautionary note regarding forwardlooking information this website contains forwardlooking information within the meaning of applicable united stated federal securities laws forwardlooking information includes but is not limited to information with respect to cumberland’s  intent belief or expectations and can be identified by the use of terminology such as “may” “will” “expect” “believe” “intend” “plan” “estimate” “should” “seek” “anticipate” and other comparable terms or the negative thereof   forwardlooking information is subject to known and unknown risks uncertainties and other factors that may cause the actual results level of activity performance or achievements of cumberland to be materially different from those expressed or implied by such forwardlooking information the forwardlooking statements made on this website relate only to events as of the date on which the statements are made cumberland undertakes no obligation to update publicly any forwardlooking statements whether as a result of new information future events or otherwise except as required by law   cumberland through its senior management from time to time make forwardlooking statements on this website concerning its expected future operations and other developments while forwardlooking statements reflect cumberland’s goodfaith beliefs and best judgment based upon current information they are not guarantees of future performance and are subject to known and unknown risks and uncertainties actual results may differ materially from the expectations contained in the forwardlooking statements as a result of various factors such factors include without limitation i legislative regulatory or other changes in the healthcare industry at the local state or federal level which increase the costs of or otherwise affect our operations ii changes in reimbursement available to cumberland by government or private payers including changes in medicare and medicaid payment levels and availability of thirdparty insurance coverage iii competition and iv changes in national or regional economic conditions including changes in interest rates and availability and cost of capital to cumberland   you are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used   accordingly you should not place undue reliance on forwardlooking information     indemnity you agree to defend indemnify and hold cumberland its subsidiaries affiliates officers directors employees and agents harmless from and against any claims liabilities damages losses and expenses including without limitation reasonable legal and accounting fees arising out of or in any way connected with your access to or use of the site services or cumberland content or your violation of these terms of use     limitation of liability you acknowledge and agree that to the maximum extent permitted by law the entire risk arising out of your access to and use of the site services and cumberland content remains with you  neither cumberland nor any other party involved in creating producing or delivering the site services or cumberland content will be liable for any direct indirect incidental special exemplary consequential or other damages including lost profits loss of data or loss of goodwill service interruption computer damage or system failure or the cost of substitute products or services arising out of or in connection with these terms of use or from the use of or inability to use the site services or cumberland content whether based on warranty contract tort including negligence negligence product liability or any other legal theory and whether or not cumberland has been informed of the possibility of such damage even if a limited remedy set forth herein is found to have failed of its essential purpose  in no event will cumberland’s aggregate liability arising out of or in connection with these terms of use or from the use of or inability to use the site services or cumberland content exceed twentyfive us dollars      some jurisdictions do not allow exclusions of liability for certain types of damages  accordingly some of the above limitations may not apply to you to the extent prohibited by law  in such cases cumberland’s liability will be limited to the fullest extent permitted by applicable law    if you are dissatisfied with any portion of the site or with these terms of use or any other policy applicable to the site your sole and exclusive remedy is to discontinue using the site  this sole and exclusive remedy is separate and independent of any other provision that limits cumberland’s liability or your remedies     controlling law and jurisdiction this site is operated by cumberland from its offices within the united states of america  cumberland makes no representation that the information in the site is appropriate or available for use in other locations and access to the site from territories where the contents of the site may be illegal is prohibited  those who choose to access this site from other locations do so on their own initiative and are responsible for compliance with applicable local laws  by using the site regardless of where you live or are located in the world you agree that these terms of use and any action related thereto will be governed by the laws of the state of tennessee without regard to its conflict of laws provisions  the exclusive jurisdiction and venue of any action with respect to the subject matter of these terms of use will be the state and federal courts located in nashville tennessee and each of the parties hereto waives any objection to jurisdiction and venue in such courts     entire agreement these terms of use constitute the entire and exclusive understanding and agreement between cumberland and you regarding the site services and cumberland content and these terms of use supersede and replace any and all prior oral or written understandings or agreements between cumberland and you regarding the site services and cumberland content     assignment you may not assign or transfer these terms of use by operation of law or otherwise without cumberland’s prior written consent  any attempt by you to assign or transfer these terms of use without such consent will be null and of no effect  subject to the foregoing these terms of use will bind and inure to the benefit of the parties their successors and permitted assigns     modification and notices cumberland reserves the right at its sole discretion to modify discontinue or terminate the site or services or to modify these terms of use at any time and without prior notice  if we modify these terms of use we will post the modification on the site  by continuing to access or use the site or the services after we have posted a modification on the site or have provided you with notice of a modification you are indicating that you agree to be bound by the modified terms of use  if the modified terms of use are not acceptable to you your only recourse is to cease using the site and services   you consent to the use of i electronic means to complete these terms of use and to deliver any notices or other communications permitted or required hereunder and ii electronic records to store information related to these terms of use or your use of the site or services any notices or other communications to be given hereunder including those regarding modifications to these terms of use will be in writing and given by posting to the site      general the failure of cumberland to enforce any right or provision of these terms of use will not constitute a waiver of future enforcement of that right or provision  the waiver of any such right or provision will be effective only if in writing and signed by a duly authorized representative of cumberland  except as expressly set forth in these terms of use the exercise by either party of any of its remedies under these terms of use will be without prejudice to its other remedies under these terms of use or otherwise  if for any reason a court of competent jurisdiction finds any provision of these terms of use invalid or unenforceable that provision will be enforced to the maximum extent permissible and the other provisions of these terms of use will remain in full force and effect     feedback and contacting cumberland if you have any questions about these terms of use please contact cumberland at privacycumberlandpharmacom   we welcome and encourage you to provide feedback comments and suggestions for improvements to the site and services “feedback”  you may submit feedback through the “contact us” section of the site  you acknowledge and agree that all feedback will be the sole and exclusive property of cumberland and may be used by cumberland for any purpose without payment or other obligation to you  you hereby irrevocably assign to cumberland and agree to irrevocably assign to cumberland all of your right title and interest in and to all feedback including without limitation all worldwide patent rights copyright rights trade secret rights and other proprietary or intellectual property rights therein  at cumberland’s request and expense you will execute documents and take such further acts as cumberland may reasonably request to assist cumberland to acquire perfect and maintain its intellectual property rights and other legal protections for the feedback   cumberland pharmaceuticals inc  west end avenue suite  nashville tennessee  site mapprivacy policyterms  conditions cumberland pharmaceuticals  coworking space in nashville foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingcumberland pharmaceuticalscoworking space and officenashvillesavesharetips cumberland pharmaceuticals tip and reviewlog in to leave a tip hereposttrish reynoldsfebruary  been here  timesthe mayor here is hot photorelated searchescumberland pharmaceuticals nashville  cumberland pharmaceuticals nashville photos  cumberland pharmaceuticals nashville location  cumberland pharmaceuticals nashville address  cumberland pharmaceuticals nashville  cumberland pharm nashville  cumberland pharmaceuticals nashville  cumberland pharmaceuticals inc nashville  aboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeymore great places in nashvilleabcdefghijklmnopqrstuvwxyzfoursquare    lovingly made in nyc  sfcumberland pharmaceuticals west end ave ste nashville tn united statesget directions likely open see when people check inpeople tend to check in during these timestoday am– am am– amnoon– pmtue am– am am– pmwed am– am am– pmthu am– pmfri am– am am– pmsat am– pm pm– pmsunnonesee moreunited states » tennessee » davidson county » nashville » professional  other places » office » coworking spaceis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around you cumberland pharmaceuticals  news releases corporate governance  cumberland pharmaceuticals search form search about usprofile  mission our strategy leadership team company histroy our products cumberland emerging technologies investor relationscorporate update corporate governance management committees board of directors contact the board stock information historic stock lookup analyst coverage ownership profile financial information sec filings annual reports quarterly results key ratios events  presentations investor faqs news releases press releases corporate updates in the news contact ir news contact us corporate headquarters cumberland pharmaceuticals inc west end avenue suite nashville tennessee  phone  toll free  fax   infocumberlandpharmacom for directions to us please see location employment opportunities employmentcumberlandpharmacom investor relations investorscumberlandpharmacom business development developmentcumberlandpharmacom wholesaler customer service phone  fax   medical information this website is not for medical emergencies if you are a patient caregiver or healthcare professional and need product related information please visit our products page which will link you to productspecific websites adverse event reporting toll free phone  for healthcare professionals only     corporate update corporate governance stock information financial information events  presentations investor faqs news releases press releases corporate updates in the news contact ir  mo  mo  yr shareholder tools search investor relations   news releases year all years      all releases clinigen and cumberland pharmaceuticals obtain fda approval for totect® in the us jul     cumberland pharmaceuticals reports revenue growth of  in first quarter  may   nashville tenn may   prnewswire  cumberland pharmaceuticals inc nasdaq cpix a specialty pharmaceutical company focused on hospital acute care and gastroenterology today announced first quarter  financial results with net revenues of  million and adjusted earnings of  million or  per share as of march    read more   cumberland pharmaceuticals to announce first quarter  financial results may   nashville tenn may   prnewswire  cumberland pharmaceuticals inc nasdaq cpix announced today that it will release first quarter  financial results after the market closes on monday may    a conference call and live internet webcast will be held on monday may   at  pm eastern time to discuss the results  read more   new kristalose® growth driver established through copromotion agreement apr   nashville tenn april   prnewswire  cumberland pharmaceuticals nasdaq cpix a us specialty pharmaceutical company and poly pharmaceuticals inc a privatelyheld us specialty pharmaceutical company have entered into a copromotion partnership for kristalose® within the united states polys sales force will more than doubl read more   caldolor® demonstrates significant post surgical pain reduction and decrease in opioid use mar   nashville tenn march   prnewswire  cumberland pharmaceuticals inc nasdaq cpix today announced the publication of a trial providing evidence that using caldolor in multimodal pain control strategies improves postoperative pain control and reduces opioid use in patients undergoing transsphenoidal surgery the trial was conducted at  read more   new vaprisol study supports a reduced dose in patients with severe liver impairment mar     cumberland pharmaceuticals reports fourth quarter and full year  financial results mar   nashville tenn march   prnewswire  cumberland pharmaceuticals inc nasdaq cpix a specialty pharmaceutical company focused on hospital acute care and gastroenterology today announced fourth quarter and full year  financial results net revenues for the year ended december   were  million with adjusted earnings of  read more   cumberland pharmaceuticals to announce fourth quarter and annual  financial results feb   nashville tenn feb   prnewswire  cumberland pharmaceuticals inc nasdaq cpix announced today that it will release fourth quarter and annual  financial results after the market closes on tuesday march    a conference call and live internet webcast will be held on tuesday march   at  pm eastern time to disc read more   showing  of  page     next   add release to briefcase cumberland pharmaceuticals inc  west end avenue suite  nashville tennessee  site mapprivacy policyterms  conditions cumberland pharmaceuticals inc private company information  bloomberg july    pm et pharmaceuticals company overview of cumberland pharmaceuticals inc snapshot people company overview cumberland pharmaceuticals inc a specialty pharmaceutical company focuses on acquiring developing and commercializing branded prescription products for hospital acute care and gastroenterology markets in the united states and internationally it marketed products include acetadote acetylcysteine injection for the treatment of acetaminophen poisoning caldolor ibuprofen injection for the treatment of pain and fever kristalose lactulose for oral solution a prescription laxative vaprisol conivaptan injection for treating hyponatremia omeclamoxpak for the treatment of h pylori infection and duodenal ulcer disease and ethyol amifostine for injection to treat oncology patient cumberland pharmaceuticals inc a specialty pharmaceutical company focuses on acquiring developing and commercializing branded prescription products for hospital acute care and gastroenterology markets in the united states and internationally it marketed products include acetadote acetylcysteine injection for the treatment of acetaminophen poisoning caldolor ibuprofen injection for the treatment of pain and fever kristalose lactulose for oral solution a prescription laxative vaprisol conivaptan injection for treating hyponatremia omeclamoxpak for the treatment of h pylori infection and duodenal ulcer disease and ethyol amifostine for injection to treat oncology patients the company’s product candidates in phase ii clinical trials comprise hepatoren ifetroban injection for the treatment of hepatorenal syndrome boxaban ifetroban oral capsule for the treatment of aspirinexacerbated respiratory disease vasculan ifetroban oral capsule for the treatment of systemic sclerosis and portaban for the treatment of portal hypertension its preapproval products consist of methotrexate injection for treating active rheumatoid juvenile idiopathic and psoriatic arthritis as well as disabling psoriasis and totect injection for emergency oncology intervention which helps to reverse the toxic effects of anthracycline chemotherapy in case of extravasation the company markets and sells its products through sales representatives and district managers cumberland pharmaceuticals inc has a strategic alliance with clinigen group plc nordic group bv and cumberland emerging technologies the company was incorporated in  and is headquartered in nashville tennessee detailed description  west end avenuesuite nashville tn united statesfounded in  employees phone  fax  wwwcumberlandpharmacom key executives for cumberland pharmaceuticals inc mr a j kazimi mba founder chairman chief executive officer and president age  total annual compensation k mr michael p bonner chief financial officer and senior director of finance  accounting age  total annual compensation k mr leo b pavliv rph chief development officer and executive vice president of operations age  total annual compensation k mr martin e cearnal chief commercial officer executive vice president and director age  total annual compensation k mr james lowrance herman chief compliance officer and senior vice president of national accounts age  total annual compensation k compensation as of fiscal year  cumberland pharmaceuticals inc key developments cumberland pharmaceuticals inc announces unaudited consolidated earnings results for the first quarter ended march   may   cumberland pharmaceuticals inc announced unaudited consolidated earnings results for the first quarter ended march   for the quarter the company announced net revenues of  compared to  for the same period a year ago operating loss was  compared to  for the same period a year ago loss before income taxes was  compared to  for the same period a year ago net loss attributable to common shareholders was  compared to  for the same period a year ago basic and diluted loss per share was  against  per share a year ago net cash provided by operating activities was  compared to  for the same period a year ago additions to property and equipment were  compared to  for the same period a year ago additions to intangible assets were  compared to  for the same period a year ago adjusted earnings were  or  per diluted share compared to  or  per diluted share for the same period a year ago cumberland pharmaceuticals inc to report q  results on may   may   cumberland pharmaceuticals inc announced that they will report q  results at  pm us eastern standard time on may   cumberland pharmaceuticals inc q  earnings call may   may   cumberland pharmaceuticals inc q  earnings call may   similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact cumberland pharmaceuticals inc please visit wwwcumberlandpharmacom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close cumberland pharmaceuticals inc  product pipeline review   trends statistics segment and forecasts market size share analysis  market research store     gmt office hours  uscan toll free  us office no home categories become publisher news about us contact us select category consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media semiconductor chemical and materials metallurgical market research search home  life sciences  pharmaceuticals cumberland pharmaceuticals inc  product pipeline review   published sep  format pdf  global markets direct  number of pages   code mrs   report details table of content inquiry for buying request sample cumberland pharmaceuticals inc  product pipeline review   summary global markets direct’s ‘cumberland pharmaceuticals inc  product pipeline review  ’ provides an overview of the cumberland pharmaceuticals inc’s pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of cumberland pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of cumberland pharmaceuticals inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of cumberland pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the cumberland pharmaceuticals inc’s pipeline products reasons to buy  evaluate cumberland pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline  assess the growth potential of cumberland pharmaceuticals inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the cumberland pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of cumberland pharmaceuticals inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of cumberland pharmaceuticals inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of cumberland pharmaceuticals inc and identify potential opportunities in those areas  avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  cumberland pharmaceuticals inc snapshot  cumberland pharmaceuticals inc overview  key information  key facts  cumberland pharmaceuticals inc  research and development overview  key therapeutic areas  cumberland pharmaceuticals inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  cumberland pharmaceuticals inc  pipeline products glance  cumberland pharmaceuticals inc  clinical stage pipeline products  phase ii productscombination treatment modalities  cumberland pharmaceuticals inc  early stage pipeline products  preclinical productscombination treatment modalities  discovery productscombination treatment modalities  cumberland pharmaceuticals inc  drug profiles  ifetroban  product description  mechanism of action  rd progress  isocitrate  product description  mechanism of action  rd progress  small molecule to inhibit gsk for acute and late radiation injury  product description  mechanism of action  rd progress  cumberland pharmaceuticals inc  pipeline analysis  cumberland pharmaceuticals inc  pipeline products by target  cumberland pharmaceuticals inc  pipeline products by route of administration  cumberland pharmaceuticals inc  pipeline products by molecule type  cumberland pharmaceuticals inc  pipeline products by mechanism of action  cumberland pharmaceuticals inc  recent pipeline updates  cumberland pharmaceuticals inc  dormant projects  cumberland pharmaceuticals inc  locations and subsidiaries  head office  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables cumberland pharmaceuticals inc key information  cumberland pharmaceuticals inc key facts  cumberland pharmaceuticals inc  pipeline by indication   cumberland pharmaceuticals inc  pipeline by stage of development   cumberland pharmaceuticals inc  monotherapy products in pipeline   cumberland pharmaceuticals inc  phase ii   cumberland pharmaceuticals inc  preclinical   cumberland pharmaceuticals inc  discovery   cumberland pharmaceuticals inc  pipeline by target   cumberland pharmaceuticals inc  pipeline by route of administration   cumberland pharmaceuticals inc  pipeline by molecule type   cumberland pharmaceuticals inc  pipeline products by mechanism of action   cumberland pharmaceuticals inc  recent pipeline updates   cumberland pharmaceuticals inc  dormant developmental projects  list of figures cumberland pharmaceuticals inc  pipeline by top  indication   cumberland pharmaceuticals inc  pipeline by stage of development   cumberland pharmaceuticals inc  monotherapy products in pipeline   cumberland pharmaceuticals inc  pipeline by top  target   cumberland pharmaceuticals inc  pipeline by top  route of administration   cumberland pharmaceuticals inc  pipeline by top  molecule type   cumberland pharmaceuticals inc  pipeline products by top  mechanism of action   inquiry for buying please fill your details below to inquire about this report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit request sample please fill your details below to receive sample report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit related reports global and china laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the global and china laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enh read more united states laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the united states laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enhanc read more europe laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the europe laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enhances the read more china laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the china laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enhances the u read more global laboratory ventilators market professional survey report forecast  mar  sp consulting  pages    code  mrs   this report studies laboratory ventilators in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  this report focuses on top manufacturers in global market with production price revenue and market share for each manufacturer covering harvard apparatus parr instrument harvard bioscience columbus instruments company  company   b read more global laboratory ventilators sales market report forecast  mar  sp consulting  pages    code  mrs   the report offers a comprehensive evaluation of the market it does so via indepth insights understanding market evolution by tracking historical developments and analyzing the present scenario and future projections based on optimistic and likely scenarios each research report serves as a repository of analysis and information for every facet of the market including but not limited to regional markets technology developments types applications and the competitive landscape the read more global laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the global laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enhances the read more global and china medical bone densitometers market research report forecast  mar  sp consulting  pages    code  mrs   the global and china medical bone densitometers market research report forecast  is a valuable source of insightful data for business strategists it provides the medical bone densitometers industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this medical bone densitometers market study provides comprehensive da read more united states medical bone densitometers market research report forecast  mar  sp consulting  pages    code  mrs   the united states medical bone densitometers market research report forecast  is a valuable source of insightful data for business strategists it provides the medical bone densitometers industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this medical bone densitometers market study provides comprehensive data read more europe medical bone densitometers market research report forecast  mar  sp consulting  pages    code  mrs   the europe medical bone densitometers market research report forecast  is a valuable source of insightful data for business strategists it provides the medical bone densitometers industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this medical bone densitometers market study provides comprehensive data which e read more payment mode single user  usd multi user  usd corporate user  usd latest report  global nonslip epoxy glass flake paint market research report  global parking sensors market research report  global nitrogen oxide sensor market research report  global nuclear density gauge market research report  global automotive interior materials market research report view more latest news global chitosan market set for rapid growth to reach usd  billion by  zion market research has published a new report titled chitosan market for water treatment biomed development of ecommerce to reshape global mobile hotspot router market mobile hotspot is a popular feature on smart phones that provide wireless internet access on many global carotenoids market is expected to reach around usd  billion in  zion market research has published a new report titled carotenoids market by type astaxanthin be soaring demand from food  beverages industry to act as prime driving for ascorbic acid market reports zion market research ascorbic acid is extensively available in nature mostly rich in leafy vegetables and fresh fruits global energy management system ems market is set for a rapid growth and is expected to reach usd  million by  zion market research has published a new report titled energy management system market ems by so view more single user  usd view pricing find help how to order disclaimer faqs return policy sitemap our company about us terms and conditions privacy policy we accept the following payment methods     market research store  market research reports cumberland pharmaceuticals inc  product pipeline review   search advance search home pharmaceuticals cumberland pharmaceuticals inc  product pipeline review   cumberland pharmaceuticals inc  product pipeline review   glo  pages december  pharmaceuticals report overview table of contents cumberland pharmaceuticals inc  product pipeline review  summaryglobal markets directs cumberland pharmaceuticals inc  product pipeline review   provides an overview of the cumberland pharmaceuticals incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of cumberland pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of cumberland pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of cumberland pharmaceuticals incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the cumberland pharmaceuticals incs pipeline productsreasons to buy evaluate cumberland pharmaceuticals incs strategic position with total access to detailed information on its product pipeline assess the growth potential of cumberland pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the cumberland pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of cumberland pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of cumberland pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of cumberland pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contentstable of contents list of tables list of figures cumberland pharmaceuticals inc snapshot cumberland pharmaceuticals inc overview key information key facts cumberland pharmaceuticals inc  research and development overview key therapeutic areas cumberland pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy cumberland pharmaceuticals inc  pipeline products glance cumberland pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities cumberland pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities cumberland pharmaceuticals inc  drug profiles ifetroban product description mechanism of action rd progress isocitrate product description mechanism of action rd progress small molecule to inhibit gsk for acute and late radiation injury product description mechanism of action rd progress cumberland pharmaceuticals inc  pipeline analysis cumberland pharmaceuticals inc  pipeline products by target cumberland pharmaceuticals inc  pipeline products by route of administration cumberland pharmaceuticals inc  pipeline products by molecule type cumberland pharmaceuticals inc  pipeline products by mechanism of action cumberland pharmaceuticals inc  recent pipeline updates cumberland pharmaceuticals inc  dormant projects cumberland pharmaceuticals inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tableslist of tablescumberland pharmaceuticals inc key information cumberland pharmaceuticals inc key facts cumberland pharmaceuticals inc  pipeline by indication  cumberland pharmaceuticals inc  pipeline by stage of development  cumberland pharmaceuticals inc  monotherapy products in pipeline  cumberland pharmaceuticals inc  phase ii  cumberland pharmaceuticals inc  preclinical  cumberland pharmaceuticals inc  discovery  cumberland pharmaceuticals inc  pipeline by target  cumberland pharmaceuticals inc  pipeline by route of administration  cumberland pharmaceuticals inc  pipeline by molecule type  cumberland pharmaceuticals inc  pipeline products by mechanism of action  cumberland pharmaceuticals inc  recent pipeline updates  cumberland pharmaceuticals inc  dormant developmental projects list of figureslist of figurescumberland pharmaceuticals inc  pipeline by top  indication  cumberland pharmaceuticals inc  pipeline by stage of development  cumberland pharmaceuticals inc  monotherapy products in pipeline  cumberland pharmaceuticals inc  pipeline by top  target  cumberland pharmaceuticals inc  pipeline by top  route of administration  cumberland pharmaceuticals inc  pipeline by top  molecule type  cumberland pharmaceuticals inc  pipeline products by top  mechanism of action   please select format    single user us       multi user us       corporate user us    add to cart buy now enquiry about report submit need more information contact us        or  helpbigmarketresearchcom   similar market studies global onychomycosis tinea unguium drug detailed analysis report  this report splits onychomycosis tinea unguium drug by product drug form by product usage type this shares the history data information from  to  and forecast from  to  and this report mainly introduces volume and value market share by players by regions by product type by consumers and  july            view details  global cord blood banking services stem cell market size share trends forecast global analysis research report segmentation and future demand    umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta cord blood is rich source of stem cell used in treatment of different chronic diseases private and public cord blood banks are the two major types of banks that are prevalent in the cord  july            view details  global and europe antiparasitic drugs market  analysis and outlook to  this report presents a comprehensive overview of the antiparasitic drugs market in europe this shares the history data information from  to  and forecast from  to  this report provides a detailed analysis of the market its dynamics structure characteristics main players growth and demand drivers etc as  july            view details  global and europe drugs of nervous system market  analysis and outlook to  this report presents a comprehensive overview of the drugs of nervous system market in europe this shares the history data information from  to  and forecast from  to  this report provides a detailed analysis of the market its dynamics structure characteristics main players growth and demand drivers  july            view details  upcoming market research reports global general medicine education publishing market type geography size share global trends company profiles demand insights analysis opportunities segmentation forecast  general medicine is a branch of medicine that deals with diagnosis and treatment of diseases associated with internal organs it is also called as internal medicine general medicine education market has shown substantial growth due to the adoption of internal medicine as a career option by medical students july      price      pre book price  read more  cancer vaccine market global scenario market size outlook trend and forecast   cancer vaccines are biological response modifiers these vaccines work by stimulating or restoring the immune system’s ability to fight against infections and diseases it is used either as standalone therapies  march      price      pre book price  read more  radiopharmaceuticals market global scenario market size outlook trend and forecast   radiopharmaceutical is a radioactive pharmaceutical agent which is used diagnostic or therapeutic procedures a radiopharmaceutical is made up of two components that are drug component and radioactive component this radioactive  march      price      pre book price  read more  pharmaceutical excipients market global scenario market size outlook trend and forecast   pharmaceutical excipients are substances other than the pharmacologically active drug or prodrug which are included in the manufacturing process or are contained in a finished pharmaceutical product dosage form the  march      price      pre book price  read more  over the counter otc  diet supplementary market global scenario market size outlook trend and forecast   over the counter otc drugs are those drugs which can be picked by consumer without the prescription of doctors intended to use for diagnosis cure mitigation treatment or prevention of  march      price      pre book price  read more  world active pharmaceutical ingredient api market  opportunities and forecasts    increase in abbreviated new drug applications anda over the past years has fostered the demand for api market furthermore indian companies making increased entries related to drug master file dmf  july      price      pre book price  read more    copyright big market research view pricing  cumberland pharmaceuticals inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports cumberland pharmaceuticals inc  product pipeline revie cumberland pharmaceuticals inc  product pipeline review   wgr  december  global  pages global markets direct description table of content sample report enquiry before buy related reports cumberland pharmaceuticals inc  product pipeline review  summaryglobal markets direct’s ‘cumberland pharmaceuticals inc  product pipeline review  ’ provides an overview of the cumberland pharmaceuticals inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of cumberland pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of cumberland pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of cumberland pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the cumberland pharmaceuticals inc’s pipeline productsreasons to buy evaluate cumberland pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of cumberland pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the cumberland pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of cumberland pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of cumberland pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of cumberland pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures cumberland pharmaceuticals inc snapshot cumberland pharmaceuticals inc overview key information key facts cumberland pharmaceuticals inc  research and development overview key therapeutic areas cumberland pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy cumberland pharmaceuticals inc  pipeline products glance cumberland pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities cumberland pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities cumberland pharmaceuticals inc  drug profiles ifetroban product description mechanism of action rd progress isocitrate product description mechanism of action rd progress small molecule to inhibit gsk for acute and late radiation injury product description mechanism of action rd progress cumberland pharmaceuticals inc  pipeline analysis cumberland pharmaceuticals inc  pipeline products by target cumberland pharmaceuticals inc  pipeline products by route of administration cumberland pharmaceuticals inc  pipeline products by molecule type cumberland pharmaceuticals inc  pipeline products by mechanism of action cumberland pharmaceuticals inc  recent pipeline updates cumberland pharmaceuticals inc  dormant projects cumberland pharmaceuticals inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablescumberland pharmaceuticals inc key information cumberland pharmaceuticals inc key facts cumberland pharmaceuticals inc  pipeline by indication  cumberland pharmaceuticals inc  pipeline by stage of development  cumberland pharmaceuticals inc  monotherapy products in pipeline  cumberland pharmaceuticals inc  phase ii  cumberland pharmaceuticals inc  preclinical  cumberland pharmaceuticals inc  discovery  cumberland pharmaceuticals inc  pipeline by target  cumberland pharmaceuticals inc  pipeline by route of administration  cumberland pharmaceuticals inc  pipeline by molecule type  cumberland pharmaceuticals inc  pipeline products by mechanism of action  cumberland pharmaceuticals inc  recent pipeline updates  cumberland pharmaceuticals inc  dormant developmental projects list of figurescumberland pharmaceuticals inc  pipeline by top  indication  cumberland pharmaceuticals inc  pipeline by stage of development  cumberland pharmaceuticals inc  monotherapy products in pipeline  cumberland pharmaceuticals inc  pipeline by top  target  cumberland pharmaceuticals inc  pipeline by top  route of administration  cumberland pharmaceuticals inc  pipeline by top  molecule type  cumberland pharmaceuticals inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send cpix key statistics  cumberland pharmaceuticals inc financial ratios  marketwatch x tweet share this bulletin get news bulletins by email bulletin kushner suggesting russia role in election outcome ridicules trumps voters » investor alert new york markets close in market snapshot winners and losers x tweet share this bulletin get news bulletins by email bulletin golds winning streak ends at six sessions » expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close cumberland pharmaceuticals inc nasdaq cpix go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus cumberland pharmaceuticals inc market open  real time quotes jul    pm cpix quoteszigmancomposite   change   volume volume  real time quotes quoteszigmancomposite previous close     change   day low day high    week low  week high   company description cumberland pharmaceuticals inc engages in the acquisition development and commercialization of branded prescription products its product brands include acetadote caldolor kristalose omeclamoxpak vaprisol and ethyol the company was founded by a j kazimi on january   and is headqua cumberland pharmaceuticals inc engages in the acquisition development and commercialization of branded prescription products its product brands include acetadote caldolor kristalose omeclamoxpak vaprisol and ethyol the company was founded by a j kazimi on january   and is headquartered in nashville tn valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  price to cash flow ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  longterm debt to equity  longterm debt to total capital  officers and executives name age officer since title mr a j kazimi   chairman  chief executive officer mr leo b pavliv   evpoperations  chief development officer mr michael p bonner   cfo senior directorfinance  accounting dr amy dix rock   senior directorregulatory  scientific affairs mr james l herman   chief compliance officer  senior vice president insider actions – purchase – sale  – number of transactions  date name shares transaction value  joey a jacobs director    award at  per share   michael p bonner chief financial officer    acquisition at  per share   jonathan i griggs director    disposition at  per share   a j kazimi chairman and ceo director    derivativenonderivative trans at  per share   martin e cearnal sr vpchief commercial officer director    derivativenonderivative trans at  per share   leo b pavliv svp and chief development off    derivativenonderivative trans at  per share   james l herman vp and chief compliance office    derivativenonderivative trans at  per share   michael p bonner chief financial officer    derivativenonderivative trans at  per share   thomas r lawrence director    disposition at  per share   a j kazimi chairman and ceo director    award at  per share   kenneth john krogulski director    award at  per share   martin e cearnal sr vpchief commercial officer director    award at  per share   gordon r bernard director    award at  per share   leo b pavliv svp and chief development off    award at  per share   joey a jacobs director    award at  per share   james l herman vp and chief compliance office    award at  per share   michael p bonner chief financial officer    award at  per share   jonathan i griggs director    award at  per share   james r jones director    award at  per share   caroline r young director    award at  per share   michael p bonner chief financial officer    acquisition at  per share   kenneth john krogulski director    acquisition at  per share   thomas r lawrence director    disposition at  per share   michael p bonner chief financial officer    acquisition at  per share   thomas r lawrence director    disposition at  per share   thomas r lawrence director    disposition at  per share   a j kazimi chairman and ceo director    derivativenonderivative trans at  per share   martin e cearnal sr vpchief commercial officer director    derivativenonderivative trans at  per share   leo b pavliv svp and chief development off    derivativenonderivative trans at  per share   james l herman vp and chief compliance office    derivativenonderivative trans at  per share   thomas r lawrence director    disposition at  per share   a j kazimi chairman and ceo director    derivativenonderivative trans at  per share   martin e cearnal sr vpchief commercial officer director    derivativenonderivative trans at  per share   leo b pavliv svp and chief development off    derivativenonderivative trans at  per share   james l herman vp and chief compliance office    derivativenonderivative trans at  per share   a j kazimi chairman and ceo director    award at  per share   martin e cearnal sr vpchief commercial officer director    award at  per share   gordon r bernard director    award at  per share   leo b pavliv svp and chief development off    award at  per share   joey a jacobs director    award at  per share   james l herman vp and chief compliance office    award at  per share   michael p bonner chief financial officer    award at  per share   jonathan i griggs director    award at  per share   james r jones director    award at  per share   thomas r lawrence director    award at  per share  newslatestcompanyuscpix marketwatch news on cpix thursday’s biggest gaining and declining stocks  pm feb    kate gibson stocks to watch thursday diamond foods six flags  am feb    marketwatch friday’s biggest gaining and declining stocks  pm jan    kate gibson drug indexes diverge cumberland rallies  pm jan    val brickates kennedy cumberland rallies as drug indexes hug flat line  am jan    val brickates kennedy wednesday’s biggest gaining and declining stocks  pm dec    robert daniel mondays biggest gaining and declining stocks  pm aug    marketwatch jazz tumbles on fda setback drug indexes mixed  pm aug    val brickates kennedy cumberland falls on fda delay  am aug    val brickates kennedy cumberland pharma shares drop   am aug    laura mandaro tuesdays biggest gaining and declining stocks  pm aug    marketwatch drugstock indexes rise as lilly mannkind slide  pm aug    val brickates kennedy updates advisories and surprises  am aug    marketwatch cumberland pharmaceuticals shares down   am aug    nick godt cumberland pharma falls on financial outlook  am aug    val brickates kennedy good news bad news for nashville health care  am july    russ britt southernfried health care  am july    russ britt tuesdays biggest gaining and declining stocks  pm nov    marketwatch newsnonmarketwatchcompanyuscpix other news on cpix cumberland pharmaceuticals inc cpix and recro pharma inc reph lead  notable investor filings  am may    investorplacecom cumberland pharmaceuticals cpix ceo aj kazimi on q  results  earnings call transcript  pm may    seeking alpha insiderinsightscom daily round up  sears lb foster company virtu financial opko health delek logistics partners  am march    seeking alpha stonepine capital management llc buys recro pharma sciclone pharmaceuticals novelion   pm march    gurufocuscom k cumberland pharmaceuticals inc  am march    edgar online  edg  q k cumberland pharmaceuticals cpix ceo aj kazimi on q  results  earnings call transcript  pm march    seeking alpha cumberland pharmaceuticals needs to fish or cut bait  pm dec    seeking alpha cumberland pharma nabs us rights to nordics injectable methotrexate  am nov    seeking alpha  pharmaceuticals stocks to sell now  am nov    investorplacecom  pharmaceuticals stocks to sell now  am nov    investorplacecom q cumberland pharmaceuticals inc  pm nov    edgar online  edg  q k cumberland pharmaceuticals cpix ceo aj kazimi on q  results  earnings call transcript  pm nov    seeking alpha cumberland pharmaceuticals little downside but upside is tough to find  am aug    seeking alpha q cumberland pharmaceuticals inc  pm aug    edgar online  edg  q k cumberland pharmaceuticals cpix ceo a j kazimi on q  results  earnings call transcript  pm aug    seeking alpha micro cap value discovery  pm july    gurufocuscom  pharmaceuticals stocks to sell now  am may    investorplacecom cumberland pharmaceuticals cpix ceo aj kazimi on q  results  earnings call transcript  pm may    seeking alpha cumberland pharmaceuticals needs a new strategy  am march    seeking alpha cumberlands cpix ceo aj kazimi on q  results  earnings call transcript  pm march    seeking alpha loading more headlines at a glance cumberland pharmaceuticals inc  west end avenue suite  nashville tennessee  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue m net income  employees  annual report for cpix newspressreleasecompanyuscpix press releases on cpix cumberland pharmaceuticals reports revenue growth of  in first quarter   pm may    pr newswire  prf investor network cumberland pharmaceuticals inc to host earnings call  pm may    accesswire cumberland pharmaceuticals to announce first quarter  financial results  pm may    pr newswire  prf new kristalose® growth driver established through copromotion agreement  am april    pr newswire  prf caldolor® demonstrates significant post surgical pain reduction and decrease in opioid use  pm march    pr newswire  prf shareholder alert levi  korsinsky llp announces an investigation concerning possible breaches of fiduciary duty by certain officers and directors of cumberland pharmaceuticals inc  am march    businesswire  bzx scleroderma diagnostics and therapeutics market  global industry analysis size share growth trends and forecast     pm march    pr newswire  prf cumberland pharmaceuticals reports fourth quarter and full year  financial results  pm march    pr newswire  prf cumberland pharmaceuticals to announce fourth quarter and annual  financial results  pm feb    pr newswire  prf caldolor® pediatric fever study published supporting its efficacy safety and pharmacokinetics  am feb    pr newswire  prf us court of appeals affirms cumberland pharmaceuticals victory in patent litigation case  am jan    pr newswire  prf cumberland pharmaceuticals announces kenneth j krogulski to join its board of directors  am jan    pr newswire  prf cumberland pharmaceuticals and clinigen enter exclusive us commercialization agreement for totect®  am jan    pr newswire  prf scleroderma diagnostics and therapeutics market  global industry analysis size share growth trends and forecast     am dec    pr newswire  prf blog coverage cumberland pharma bags exclusive rights for europe based nordic group injectable methotrexate product line for the us market  am nov    accesswire cumberland pharmaceuticals acquires us rights to nordic groups methotrexate injection products  am nov    pr newswire  prf cumberland pharmaceuticals presentation now available for ondemand viewing  am nov    pr newswire  prf savara pharmaceuticals appoints david l lowrance as cfo  am nov    pr newswire  prf cumberland pharmaceuticals reports third quarter  year to date  financial results  pm nov    pr newswire  prf public company executives to present online to investors on november   am oct    pr newswire  prf loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pkushner ‘i did not collude with russia’ pgold settles a few cents lower ends sixsession streak of gains paugust gold down  cents to settle at oz p‘my family lost  of our silicon valley income — and we’ve never been happier’ ptrump boom not so far gdp to show us economic recovery still historically weak psinus sufferers spend billions of dollars a year to stop sniffling pinvestors withdraw from longdated treasurys etf pdow and sp  slide while nasdaq sets fresh intraday record p‘game of thrones’ the four biggest takeaways from stormborn’ ptulips financial bloggers shun bitcoin even after one of their own takes the plunge p‘flash boys’ katsuyama sees ‘flash crashes’ as the biggest risk in the stock market pwhat to do if a colleague starts stealing your responsibilities at work– just like what’s going on in trump’s white house pkushner says he did not collude with russia pjared kushner says all of his actions were proper pbreakingdow slides  points or  to  pbreakingsp  slips  points or  to  pbreakingnasdaq advances to touch alltime high of  ptrump administration stymies push for improved climaterisk disclosure among companies p of the best places to see the ‘great american eclipse’ on aug  pmcdonald’s earnings sales expected to be boosted by menu franchisee changes loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  cumberland pharmaceuticals search form search about usprofile  mission our strategy leadership team company history our products cumberland emerging technologies investor relationscorporate update corporate governancemanagement board of directors stock informationanalyst coverage historic stock lookup ownership profile financial informationsec fillings annual reports quarterly results key ratios events calender investor faqs news releasespress releases corporate updates in the news contact ir news contact us corporate headquarters cumberland pharmaceuticals inc  west end avenue suite  nashville tennessee  phone   toll free   fax   infocumberlandpharmacom for directions to us please see location employment opportunities employmentcumberlandpharmacom investor relations investorscumberlandpharmacom business development developmentcumberlandpharmacom wholesaler customer service phone   fax   medical information this website is not for medical emergencies if you are a patient caregiver or healthcare professional and need product related information please visit our products page which will link you to productspecific websites adverse event reporting toll free phone   for healthcare professionals only     providing solutions cumberland pharmaceuticals is a unique company with quality products that deliver real patient solutions every day quality products acetadote is an fdaapproved iv treatment for acetaminophen overdose currently being used in more than  us hospitals improving care caldolor is the first injectable treatment for pain and fever approved in the us driving success kristalose is the only prescription laxative product available in a powder formulation expanding pipeline hepatoren currently in phase ii is an injection intended to treat patients suffering from hepatorenal syndrome learn more about recent company developments from cumberland pharmaceuticals’ founder and ceo aj kazimiread message recent news july   clinigen and cumberland pharmaceuticals obtain fda approval for totect® in the us may   cumberland pharmaceuticals reports revenue growth of  in first quarter  view all cpix common stock exchange nasdaq open  price  change   volume  data as of monday   pm et minimum  minute delay cumberland pharmaceuticals inc  west end avenue suite  nashville tennessee   site mapprivacy policyterms  conditions cumberland pharmaceuticals  coworking space in nashville foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingcumberland pharmaceuticalscoworking space and officenashvillesavesharetips cumberland pharmaceuticals tip and reviewlog in to leave a tip hereposttrish reynoldsfebruary  been here  timesthe mayor here is hot photorelated searchescumberland pharmaceuticals nashville  cumberland pharmaceuticals nashville photos  cumberland pharmaceuticals nashville location  cumberland pharmaceuticals nashville address  cumberland pharmaceuticals nashville  cumberland pharm nashville  cumberland pharmaceuticals nashville  cumberland pharmaceuticals inc nashville  aboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeymore great places in nashvilleabcdefghijklmnopqrstuvwxyzfoursquare    lovingly made in nyc  sfcumberland pharmaceuticals west end ave ste nashville tn united statesget directions likely open see when people check inpeople tend to check in during these timestoday am– am am– amnoon– pmtue am– am am– pmwed am– am am– pmthu am– pmfri am– am am– pmsat am– pm pm– pmsunnonesee moreunited states » tennessee » davidson county » nashville » professional  other places » office » coworking spaceis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around youtrishs tip at cumberland pharmaceuticals foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingcumberland pharmaceuticalscoworking space and officenashvillesavesharetips cumberland pharmaceuticals tip and reviewlog in to leave a tip hereposttrish reynoldsfebruary  been here  timesthe mayor here is hot photorelated searchescumberland pharmaceuticals nashville  cumberland pharmaceuticals nashville photos  cumberland pharmaceuticals nashville location  cumberland pharmaceuticals nashville address  cumberland pharmaceuticals nashville  cumberland pharm nashville  cumberland pharmaceuticals nashville  cumberland pharmaceuticals inc nashville  aboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeymore great places in nashvilleabcdefghijklmnopqrstuvwxyzfoursquare    lovingly made in nyc  sfcumberland pharmaceuticals west end ave ste nashville tn united statesget directions likely open see when people check inpeople tend to check in during these timestoday am– am am– amnoon– pmtue am– am am– pmwed am– am am– pmthu am– pmfri am– am am– pmsat am– pm pm– pmsunnonesee moreunited states » tennessee » davidson county » nashville » professional  other places » office » coworking spaceis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around youcumberland pharmaceuticals  coworking space in nashville foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingcumberland pharmaceuticalscoworking space and officenashvillesavesharetips cumberland pharmaceuticals tip and reviewlog in to leave a tip hereposttrish reynoldsfebruary  been here  timesthe mayor here is hot photorelated searchescumberland pharmaceuticals nashville  cumberland pharmaceuticals nashville photos  cumberland pharmaceuticals nashville location  cumberland pharmaceuticals nashville address  cumberland pharmaceuticals nashville  cumberland pharm nashville  cumberland pharmaceuticals nashville  cumberland pharmaceuticals inc nashville  aboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeymore great places in nashvilleabcdefghijklmnopqrstuvwxyzfoursquare    lovingly made in nyc  sfcumberland pharmaceuticals west end ave ste nashville tn united statesget directions likely open see when people check inpeople tend to check in during these timestoday am– am am– amnoon– pmtue am– am am– pmwed am– am am– pmthu am– pmfri am– am am– pmsat am– pm pm– pmsunnonesee moreunited states » tennessee » davidson county » nashville » professional  other places » office » coworking spaceis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around you yelp yelp sorry you’re not allowed to access this page contact yelp if you keep experiencing issues bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one